• 1
    Fast Stats: Esophagus Cancer. Available at: Accessed July 15, 2008.
  • 2
    Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001; 92: 54955.
  • 3
    Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 82531.
  • 4
    Farrow DC, Vaughan TL, Sweeney C, et al. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control 2000; 11: 2318.
  • 5
    Wu AH, Tseng CC, Bernstein L. Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma. Cancer 2003; 98: 9408.
  • 6
    Anderson LA, Watson RG, Murphy SJ, et al. Risk factors for Barrett’s oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol 2007; 13: 158594.
  • 7
    Whiteman DC, Sadeghi S, Pandeya N, et al. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut 2008; 57: 17380.
  • 8
    Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett’s esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 102832.
    Direct Link:
  • 9
    Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett’s esophagus. Am J Gastroenterol 2002; 97: 188895.
    Direct Link:
  • 10
    Armstrong D, Marshall JK, Chiba N, et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults – update 2004. Can J Gastroenterol 2005; 19: 1535.
  • 11
    Sox HC, Greenfield S, eds. Initial national priorities for comparative effectiveness research. In: Medicine. Washington, DC: The National Academies Press, 2009.
  • 12
    Bax L, Yu L, Ikeda N, Tsuruta H, Moons K. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Med Res Methodol 2006; 6: 50.
  • 13
    MIX: Comprehensive Free Software for Meta-Analysis of Causal Research Data – Version 1.7. Available at:
  • 14
    Chow WH, Finkle WD, McLaughlin JK, Frankl H, Ziel HK, Fraumeni JF Jr. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 1995; 274: 4747.
  • 15
    Crane SJ, Locke GR III, Harmsen WS, et al. Subsite-specific risk factors for esophageal and gastric adenocarcinoma. Am J Gastroenterol 2007; 102: 1596602.
    Direct Link:
  • 16
    Chow WH, Blot WJ, Vaughan TL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998; 90: 1505.
  • 17
    Corley DA, Kubo A, Zhao W. Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomarkers Prev 2008; 17: 3528.
  • 18
    Tait VK, Birkett NJ, Maziak DE. Dietary iron intake, reflux symptoms and the risk of esophageal adenocarcinoma (EAC): analysis of a case-control study. Proc Am Assoc Cancer Res Ann Meet 2006; 47: 945.
  • 19
    Wang KK, Sampliner RE, Practice Parameters Committee of the American College of G. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol 2008; 103: 78897.
    Direct Link:
  • 20
    Wang KK, Wongkeesong M, Buttar NS. American Gastroenterological Association technical review on the role of the gastroenterologist in the management of esophageal carcinoma. Gastroenterology 2005; 128: 1471505.
  • 21
    McElholm AR, McKnight A-J, Patterson CC, et al. A population-based study of IGF axis polymorphisms and the esophageal inflammation, metaplasia, adenocarcinoma sequence. Gastroenterology 2010; 139: 20412.e3.
  • 22
    MacDonald K, Porter GA, Guernsey DL, Zhao R, Casson AG. A polymorphic variant of the insulin-like growth factor type I receptor gene modifies risk of obesity for esophageal adenocarcinoma. Cancer Epidemiol 2009; 33: 3740.
  • 23
    Neale RE, Doecke JD, Pandeya N, et al. Does type 2 diabetes influence the risk of oesophageal adenocarcinoma? Br J Cancer 2009; 100: 7958.
  • 24
    Rubenstein JH, Kao JY, Madanick RD, et al. Association of adiponectin multimers with Barrett’s esophagus. Gut 2009; 58: 15839.
  • 25
    Kendall BJ, Macdonald GA, Hayward NK, et al. Leptin and the risk of Barrett’s oesophagus. Gut 2008; 57: 44854.